Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.

Add to Collection

2014 Aug Others GR Fulcher, JS Christiansen, G Bantwal… - Diabetes …, 2014 - Am Diabetes Assoc 109

Full Author : ['Fulcher, Gregory R', 'Christiansen, Jens Sandahl', 'Bantwal, Ganapathi', 'Polaszewska-Muszynska, Miroslawa', 'Mersebach, Henriette', 'Andersen, Thomas H', 'Niskanen, Leo K']
Journal Title : Diabetes care
Chapter : Section3
Journal Year : 2014
Cited by : 135.0

OBJECTIVE: Insulin degludec/insulin aspart (IDegAsp) is the first combination of a basal insulin with an ultralong duration of action, and a rapid-acting insulin in a single injection. This trial compared IDegAsp with biphasic insulin aspart 30 (BIAsp 30)..... Read More

Keywords : ["uncontrolled insulintreated type diabetes", "phase randomize treattotarget trial", "insulin degludecinsulin aspart", "biphasic insulin aspart", "comparison"]
PubMed Link : https://diabetesjournals.org/care/article-abstract/37/8/2084/30093
Google Scholar Link : https://scholar.google.com/scholar?cites=9111812475495633938&as_sdt=2005&sciodt=0,5&hl=en&num=20

Have a Question?

Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.